NYSE
Nuvation Bio Inc. Class A (NUVB)
♥ 629 Thanks from members
Nuvation Bio Inc. (NUVB) exhibits a robust market sentiment driven by strong Q2 2026 revenue of $31.7 million, powered by IBTROZI's growth in first-line ROS1-positive non-small cell lung cancer, supported by a healthy $661 million balance sheet.